Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study. - Shen, Rong; Cao, Wei‐Guo; Wang, Li; Sheng, Ling‐Shuang; Zhang, Yi‐Lun; Wu, Wen; Xu, Peng‐Peng; Cheng, Shu; Liu, Meng‐Ke; Dong, Yan; Wang, Yue; Weng, Xiang‐Qin; et al. (Clinical & Translational Medicine, 2025)